The Relationship Between 10 Years Risk of Cardiovascular Disease and Schizophrenia Symptoms: Preliminary Results

Overview

Journal Psychiatry Investig

Specialty Psychiatry

Date 2019 Dec 6

PMID 31801314

Citations 3

Authors

Esin Evren Kilicaslan

Merve Karakilic

Almila Erol

Affiliations

Soon will be listed here.

Abstract

Objective: Previous research shows that patients with schizophrenia have increased cardiovascular disease risk than general population. Increased cardiovascular risk in schizophrenia patients have been associated with many reasons such as antipsychotic drugs, genetic predisposition, andlifestyle. In this study, we aimed to investigate the relationship between the risk of heart disease and schizophrenia symptomatology.

Methods: The 10-year cardiovascular risk was assessed by the Framingham Risk Score (FRS) in 103 patients with schizophrenia and in 39 healthy controls. Sociodemographic characteristics, age at schizophrenia onset, duration of illness, number of hospitalizations, the course of the disease and antipsychotic medications were recorded. Patients' symptoms were evaluated via The Scale for the Assessment of Negative Symptoms (SANS), The Scale for the Assessment of Positive Symptoms (SAPS), and Calgary Depression Scale for Schizophrenia (CDSS).

Results: Ten-year cardiovascular risk was 5.16% inpatients with schizophrenia, and 3.02% in control group (p=0.030). No significant correlation was found between FRS scores, SANS, SAPS, and CDSS scores. However, FRS scores were significantly correlated with age, number of hospitalizations and duration of disease (r=0.300, 0.261, 0.252, respectively). Moreover FRS scores were higher (p=0.008) and high-density lipoprotein (HDL) levels were lower (p=0.048) in patients using multiple antipsychotics.

Conclusion: Our findings suggest a relationship between the risk of cardiovascular disease and the duration and overall severity of schizophrenia and also highlights the role of antipsychotics in this relationship.

Citing Articles

The Relationship of Ten-Year Cardiovascular Disease Risk and Clinical Features in Patients with Schizophrenia.

Kapici Y, Guc B, Tekin A, Abus S Noro Psikiyatr Ars. 2023; 60(3):231-235.

PMID: 37645081 PMC: 10461760. DOI: 10.29399/npa.28292.

Electrocardiogram abnormalities and associated factors among psychiatric patients attending follow up at Jimma Medical Center Psychiatry Clinic, Jimma, Ethiopia: an institution-based cross-sectional study.

Girma B, Wondie A, Debebe W, Juhar A, Tegene E, Bedane D BMC Cardiovasc Disord. 2023; 23(1):178.

PMID: 37005595 PMC: 10066966. DOI: 10.1186/s12872-023-03092-3.

Cardiovascular disease in older people with serious mental illness: Current challenges and future directions.

Chin K, Ghosh S, Subramaniam H, Beishon L Front Psychiatry. 2023; 14:1110361.

PMID: 36926467 PMC: 10011471. DOI: 10.3389/fpsyt.2023.1110361.

References

Barnett A, Mackin P, Chaudhry I, Farooqi A, Gadsby R, Heald A . Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol. 2007; 21(4):357-73. DOI: 10.1177/0269881107075509. View

Rosa F, Schreiner A, Thomas P, Sherif T . Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable. Clin Drug Investig. 2012; 32(4):267-79. DOI: 10.2165/11599080-000000000-00000. View

Barak Y, Swartz M, Plopsky I . Assessing cardiovascular risks of olanzapine treatment: a 6-month study versus haloperidol in schizophrenia patients. Int Clin Psychopharmacol. 2005; 20(6):315-7. DOI: 10.1097/00004850-200511000-00006. View

Sanchez-Martinez V, Romero-Rubio D, Abad-Perez M, Descalzo-Cabades M, Alonso-Gutierrez S, Salazar-Fraile J . Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics. Endocr Metab Immune Disord Drug Targets. 2017; 18(4):379-387. DOI: 10.2174/1871530317666171120151201. View

Gardiner E, Beveridge N, Wu J, Carr V, Scott R, Tooney P . Imprinted DLK1-DIO3 region of 14q32 defines a schizophrenia-associated miRNA signature in peripheral blood mononuclear cells. Mol Psychiatry. 2011; 17(8):827-40. PMC: 3404364. DOI: 10.1038/mp.2011.78. View

Daumit G, Dickerson F, Wang N, Dalcin A, Jerome G, Anderson C . A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med. 2013; 368(17):1594-602. PMC: 3743095. DOI: 10.1056/NEJMoa1214530. View

Andreasen N . Methods for assessing positive and negative symptoms. Mod Probl Pharmacopsychiatry. 1990; 24:73-88. DOI: 10.1159/000418013. View

Ryan M, Collins P, Thakore J . Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 2003; 160(2):284-9. DOI: 10.1176/appi.ajp.160.2.284. View

Allison D, Fontaine K, Heo M, Mentore J, Cappelleri J, Chandler L . The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry. 1999; 60(4):215-20. DOI: 10.4088/jcp.v60n0402. View

10.

De Leon J, Susce M, Diaz F, Rendon D, Velasquez D . Variables associated with alcohol, drug, and daily smoking cessation in patients with severe mental illnesses. J Clin Psychiatry. 2006; 66(11):1447-55. DOI: 10.4088/jcp.v66n1112. View

11.

Lee J, Heng D, Ma S, Chew S, Hughes K, Tai E . The metabolic syndrome and mortality: the Singapore Cardiovascular Cohort Study. Clin Endocrinol (Oxf). 2008; 69(2):225-30. DOI: 10.1111/j.1365-2265.2008.03174.x. View

12.

Emsley R, Oosthuizen P, Koen L, Niehaus D, Medori R, Rabinowitz J . Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther. 2009; 30(12):2378-86. DOI: 10.1016/j.clinthera.2008.12.020. View

13.

Wilson P, DAgostino R, Levy D, Belanger A, Silbershatz H, Kannel W . Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97(18):1837-47. DOI: 10.1161/01.cir.97.18.1837. View

14.

Bobes J, Arango C, Garcia-Garcia M, Rejas J . Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr Res. 2010; 119(1-3):101-9. DOI: 10.1016/j.schres.2010.02.1030. View

15.

Chapman S, Ragg M, McGeechan K . Citation bias in reported smoking prevalence in people with schizophrenia. Aust N Z J Psychiatry. 2009; 43(3):277-82. DOI: 10.1080/00048670802653372. View

16.

De Leon J . Smoking and vulnerability for schizophrenia. Schizophr Bull. 1996; 22(3):405-9. DOI: 10.1093/schbul/22.3.405. View

17.

Correll C, Frederickson A, Kane J, Manu P . Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry. 2006; 67(4):575-83. DOI: 10.4088/jcp.v67n0408. View

18.

Yazici M, Yagcioglu A, Ertugrul A, Eni N, Karahan S, Karaagaoglu E . The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey. Eur Arch Psychiatry Clin Neurosci. 2010; 261(1):69-78. DOI: 10.1007/s00406-010-0118-x. View

19.

Burghardt K, Grove T, Ellingrod V . Endothelial nitric oxide synthetase genetic variants, metabolic syndrome and endothelial function in schizophrenia. J Psychopharmacol. 2013; 28(4):349-56. PMC: 4039171. DOI: 10.1177/0269881113516200. View

20.

Hansen T, Ingason A, Djurovic S, Melle I, Fenger M, Gustafsson O . At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia. Biol Psychiatry. 2011; 70(1):59-63. DOI: 10.1016/j.biopsych.2011.01.031. View